Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies.

S Sajith Kumar Bhavani Shankara Bagepally

Published in: Expert review of pharmacoeconomics & outcomes research (2023)

Based on the available evidence during the study period, TNF-a-i is not a cost-effective option for treating RA compared to other DMARDs. However, high heterogeneity and low confidence in GRADE quality assessment preclude the results from being generalizable.

Keyphrases

rheumatoid arthritis
disease activity
interstitial lung disease
systemic lupus erythematosus
case control
systemic sclerosis
idiopathic pulmonary fibrosis